(Q44058340)

29 November 2017

title

Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization (English)

1 reference

29 November 2017

0 references

1 reference

7

1 reference

29 November 2017

Anne-Marte B Kran

1

1 reference

29 November 2017

Maja A Sommerfelt

2

1 reference

29 November 2017

Birger Sørensen

3

1 reference

29 November 2017

Jørgen Nyhus

4

1 reference

29 November 2017

Ingebjørg Baksaas

5

1 reference

29 November 2017

Johan N Bruun

6

1 reference

29 November 2017

language of work or name

English

0 references

publication date

7 April 2005

1 reference

29 November 2017

1 reference

29 November 2017

volume

23

1 reference

29 November 2017

issue

31

1 reference

29 November 2017

page(s)

4011-4015

1 reference

T cell dynamics in HIV-1 infection

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.010

Present status of human HIV vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.010

Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.010

Progress on new vaccine strategies against chronic viral infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.010

Current prospects for the development of a therapeutic vaccine for the treatment of HIV type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.010

Therapeutic dendritic-cell vaccine for chronic HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.010

HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.010

Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.010

Proliferation responses to HIVp24 during antiretroviral therapy do not reflect improved immune phenotype or function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.010

Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.010

Divergent in vitro and in vivo correlates of HIV-specific T-cell responses during onset of HIV viraemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.010

Progress in defining CD4 helper cell responses in chronic viral infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.010

HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.010

Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.010

Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.010

Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.010

Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.010

10.1016/J.VACCINE.2005.03.010

7 January 2021

Identifiers

DOI

1 reference

29 November 2017

1 reference